

Table S1 Baseline demographic and clinical characteristics of the training and validation cohorts

Characteristics	GSE62564 (training) (n=498)	GSE181559 (validation 1) (n=97)	TARGET-NBL (validation 2) (n=161)
Age at diagnosis (months)	14.6 (0.0–295.1)	12.8 (0.0–127.0)	34.9 (0.1–197.8)
<18	305 (61.2)	55 (56.7)	29 (18.0)
≥18	193 (38.8)	41 (42.3)	125 (77.6)
INSS			
Stage 1	121 (24.3)	23 (23.7)	0 (0.0)
Stage 2	78 (15.7)	9 (9.3)	1 (0.6)
Stage 3	63 (12.7)	15 (15.5)	6 (3.7)
Stage 4	183 (36.7)	32 (33.0)	126 (78.3)
Stage 4S	53 (10.6)	18 (18.6)	21 (13.0)
Unknown	0 (0.0)	0 (0.0)	7 (4.3)
MYCN			
Amplified	92 (18.5)	17 (17.5)	33 (20.5)
Non-amplified	401 (80.5)	80 (82.5)	120 (74.5)
Unknown	5 (1.0)	0 (0.0)	8 (5.0)

Data are presented as median (range) or n (%). INSS, International Neuroblastoma Staging System.